14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ADPT vs BHVN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Adaptive Biotechnologies Corporation (ADPT) is the stronger overall head-to-head candidate over Biohaven Ltd. (BHVN) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ADPT carries a Unified Composite Score of 43.8/100 (HOLD) at $27.94 (N/M Forward P/E, -16.2% operating margin), whereas BHVN carries 42.1/100 (HOLD) at $13.95 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: ADPT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 52.4); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADPT vs BHVN. Trailing 12-month operating profitability (ADPT -16.2% vs BHVN 0.0%) and valuation multiples (ADPT N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ADPT vs BHVN Key Questions & Quantitative Answers
As of Nov 16, 2026, Adaptive Biotechnologies Corporation (ADPT) is the stronger overall head-to-head candidate over Biohaven Ltd. (BHVN) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ADPT carries a Unified Composite Score of 43.8/100 (HOLD) at $27.94 (N/M Forward P/E, -16.2% operating margin), whereas BHVN carries 42.1/100 (HOLD) at $13.95 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ADPT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 52.4); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BHVN leads the Growth & Scale pillar: ADPT posts -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin), compared with BHVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ADPT generates $298M in USD-normalized revenue versus N/A for BHVN. In operating R&D and SG&A reinvestment, ADPT deploys 62.4% of Rev ($186M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BHVN.
ADPT screens cheaper on headline valuation multiples. ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (-3.0% FCF margin), whereas BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADPT (-36.4% ROE) versus BHVN (-799.5% ROE) capital efficiency.
In options market volatility and institutional positioning, ADPT carries 74.2% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.74β · 60% Vol realized risk). By comparison, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.40β · 111% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.